ETX 0462
Alternative Names: ETX-0462Latest Information Update: 28 Mar 2024
At a glance
- Originator Entasis Therapeutics
- Class Antibacterials; Small molecules
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gram-negative infections; Pseudomonal infections
Highest Development Phases
- No development reported Gram-negative infections; Pseudomonal infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (IV)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (IV)
- 29 Jul 2022 Antimicrobial data from from preclinical studies in Gram -negative infections released by Entasis Therapeutics